Table 1. KRAS mutations in 300 consecutive samples analyzed by Sanger sequencing and ASLNAqPCR.
| Tissue | KRAS | No amplifiable DNA | ||
| Mutated by SSEQ (%) | Mutated by ASLNA (%) | SSEQ (%) | ASLNA (%) | |
| COLON CRC ( n = 234) | 80/209 (38.3) | 94/221 (44.8) | 25/234 (10.7) | 13/234 (5.6) |
| Primary (n = 163) | 56/146 (38.4) | 69/153 (45.1) | 17/163 (10.4) | 10/163 (6.1) |
| Metastatic (n = 71) | 24/63 (38.1) | 25/68 (36.7) | 8/71 (11.3) | 3/71 (4.2) |
| LUNG NSCLC ( n = 38) | 16/38 (42.1) | 17/37 (45.9) | 0/38 (0) | 1/38 (0) |
| Primary (n = 29) | 9/29 (31.0) | 12/29 (41.4) | 0/29 (0) | 0/29 (0) |
| Metastatic (n = 9) | 7/9 (77.8) | 5/8 (62.5) | 0/9 (0) | 1/9 (11.1) |
| PANCREAS (n = 21) | 7/21 (33.3) | 6/21 (28.6) | 0/21 (0) | 0/21 (0) |
| Carcinoma (n = 9) | 4/9 (44.4) | 4/9 (44.4) | 0/9 (0) | 0/9 (0) |
| Cyst Fluid (n = 12) | 3/12 (25.0) | 2/12 (16.7) | 0/12 (0) | 0/12 (0) |
| THYROID (n = 7) | 0/6 (0) | 0/7 (0) | 1/7 (14.3) | 0/7 (0) |
| PTC-Classic (n = 3) | 0/3 (0) | 0/3 (0) | 0/3 (0) | 0/3 (0) |
| PTC-Others (n = 4) | 0/3 (0) | 0/4 (0) | 1/4 (25) | 0/4 (0) |
SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 3′-locked nucleic acid modified primers (ASLNAqPCR); CRC, colonic adenocarcinoma; NSCLC, lung adenocarcinoma; PTC, papillary thyroid carcinoma.